Severity
Critical
FDA Drug recall · Reported August 10, 2022
Marketed Without an Approved NDA/ANDA: Analytical testing showed the presence of tadalafil.
Ultra Supplement LLC recalled SUSTANGO (Pendenadril Tytrate Blend) Capsules, 400 mg, 10-count blisters per carton, Form… - a critical-severity action.
SUSTANGO (Pendenadril Tytrate Blend) Capsules, 400 mg, 10-count blisters per carton, Form… was recalled by Ultra Supplement LLC in August 10, 2022. Reason: Marketed Without an Approved NDA/ANDA: Analytical testing showed the presence of tadalafil.. Check the official notice for the remedy. Verify recall #D-1350-2022 with the FDA Drug before acting.
The recall
Ultra Supplement LLC issued this critical-severity FDA Drug recall-Marketed Without an Approved NDA/ANDA: Analytical testing showed the presence of tadalafil..
Sourced from official FDA Drug enforcement records. Verify recall #D-1350-2022 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-1350-2022) was formally reported on August 10, 2022, with the manufacturer initiating the action on July 21, 2022. It is classified under Critical severity (Class I), with a current status of Terminated. Ultra Supplement LLC is listed as the recalling firm, operating out of Wilmington, DE. Federal records list the affected scope as 750 cartons.
The documented reason for this recall is: Marketed Without an Approved NDA/ANDA: Analytical testing showed the presence of tadalafil. Distribution data in the federal record shows the product reached: Product was distributed nationwide in the USA via Amazon Marketplace on www.amazon.com.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified high severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Critical
Affected scope
750 cartons
Related Recalls
6
5 from same agency
SUSTANGO (Pendenadril Tytrate Blend) Capsules, 400 mg, 10-count blisters per carton, Formulated by: Male FX Labs, Bangor, ME, ASIN X0024468I9.
Marketed Without an Approved NDA/ANDA: Analytical testing showed the presence of tadalafil.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Critical (Class I) |
| Status | Terminated |
| Recall number | D-1350-2022 |
| Date reported | August 10, 2022 |
| Date initiated | July 21, 2022 |
| Recalling firm | Ultra Supplement LLC |
| Firm location | Wilmington, DE |
| Affected scope | 750 cartons |
| Distribution | Product was distributed nationwide in the USA via Amazon Marketplace on www.amazon.com. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported August 10, 2022. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.